Ratings Yield10 Bioscience

Equities

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
5.6 ^USD	+1.80%		+5.20%	-2.49%

Apr. 01	Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Apr. 01	Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality